| Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain (NCT00036335) | Eli Lilly and Company | 2002-03-01 |
| Study of gp75 Vaccine in Patients With Stage III and IV Melanoma (NCT00034554) | Eli Lilly and Company | 2002-03-01 |
| A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer (NCT00034268) | Eli Lilly and Company | 2002-03-01 |
| A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease (NCT00191373) | Eli Lilly and Company | 2002-03-01 |
| Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen (NCT00332553) | Eli Lilly and Company | 2002-02-01 |
| A Phase III Trial For Patients With Metastatic Breast Cancer (NCT00191152) | Eli Lilly and Company | 2002-02-01 |
| Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence (NCT00190606) | Eli Lilly and Company | 2002-01-01 |
| A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma (NCT00190762) | Eli Lilly and Company | 2001-10-01 |
| Biomechanical Effects of Duloxetine on Bladder and Sphincter Muscle Function in Women in Pure Genuine Stress Incontinence (NCT00190567) | Eli Lilly and Company | 2001-10-01 |
| Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis (NCT00035256) | Eli Lilly and Company | 2001-10-01 |
| A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis (NCT00034476) | Eli Lilly and Company | 2001-10-01 |
| Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer (NCT00191230) | Eli Lilly and Company | 2001-09-01 |
| Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia (NCT00034801) | Eli Lilly and Company | 2001-09-01 |
| Open Label Phase III Duloxetine Study for Stress Urinary Incontinence (NCT00191204) | Eli Lilly and Company | 2001-09-01 |
| Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia (NCT00036088) | Eli Lilly and Company | 2001-08-01 |
| Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin (NCT00036504) | Eli Lilly and Company | 2001-08-01 |
| A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury (NCT00036062) | Eli Lilly and Company | 2001-08-01 |
| Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder (NCT00034580) | Eli Lilly and Company | 2001-08-01 |
| Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer (NCT00191256) | Eli Lilly and Company | 2001-06-01 |
| Efficacy and Safety of Duloxetine (NCT00190619) | Eli Lilly and Company | 2001-05-01 |
| Duloxetine in the Treatment of Stress Urinary Incontinence. (NCT00191087) | Eli Lilly and Company | 2001-04-01 |
| The Forteo Alendronate Comparator Trial (NCT02416271) | Eli Lilly and Company | 2001-04-01 |
| The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder (NCT00044187) | Eli Lilly and Company | 2001-04-01 |
| To Evaluate the Safety in Patients Taking Duloxetine for Stress Urinary Incontinence (NCT00190632) | Eli Lilly and Company | 2001-03-01 |
| To Evaluate the Safety of Duloxetine in Patients With Stress Urinary Incontinence (NCT00190645) | Eli Lilly and Company | 2001-02-01 |
| Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature (NCT00191074) | Eli Lilly and Company | 2001-02-01 |
| A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment (NCT00190697) | Eli Lilly and Company | 2001-01-01 |
| Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer (NCT00034541) | Eli Lilly and Company | 2000-12-01 |
| Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC (NCT00191126) | Eli Lilly and Company | 2000-09-01 |
| Long-Term, Open Label Atomoxetine Study (NCT00190684) | Eli Lilly and Company | 2000-08-01 |
| Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer (NCT00006459) | Eli Lilly and Company | 2000-07-01 |
| Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome (NCT00190658) | Eli Lilly and Company | 2000-02-01 |
| The Effect of Growth Hormone in Very Young Girls With Turner Syndrome (NCT00406926) | Eli Lilly and Company | 1999-08-01 |
| Observational Study of Somatropin Treatment in Children (NCT01088412) | Eli Lilly and Company | 1999-04-01 |
| Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency (NCT00490191) | Eli Lilly and Company | 1999-01-01 |
| Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer (NCT00003669) | Eli Lilly and Company | 1998-11-01 |
| Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer (NCT00003670) | Eli Lilly and Company | 1998-10-01 |
| Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG (NCT00037713) | Eli Lilly and Company | 1998-09-01 |
| Raloxifene Use for The Heart (NCT00190593) | Eli Lilly and Company | 1998-06-01 |
| Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients (NCT00570011) | Eli Lilly and Company | 1997-06-01 |
| Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis (NCT00670501) | Eli Lilly and Company | 1996-08-01 |
| Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis (NCT00670319) | Eli Lilly and Company | 1994-11-01 |
| Somatropin Treatment to Final Height in Turner Syndrome (NCT00191113) | Eli Lilly and Company | 1989-02-01 |
| ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer (NCT00034463) | Eli Lilly and Company | |
| A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer. (NCT00034489) | Eli Lilly and Company | |
| Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19 (NCT04603651) | Eli Lilly and Company | |
| A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia (NCT00089869) | Eli Lilly and Company | |
| A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer. (NCT00034502) | Eli Lilly and Company | |
| ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer. (NCT00051506) | Eli Lilly and Company | |
| Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer (NCT03763604) | Eli Lilly and Company | |
| A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium (NCT00034593) | Eli Lilly and Company | |
| Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation (NCT03906331) | Eli Lilly and Company | |
| Pre-approval Expanded Access of Retatrutide (LY3437943) (NCT07629401) | Eli Lilly and Company | |
| An Expanded Access Program for AM0010 (Pegilodecakin) (NCT03554434) | Eli Lilly and Company | |
| Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France (NCT02307812) | Eli Lilly and Company | |
| Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors (NCT07675057) | Eli Lilly and Company | |
| A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium (NCT00035061) | Eli Lilly and Company | |
| Master Rollover Protocol for Continued Safety Assessment of Study Drug (NCT02632994) | Eli Lilly and Company | |
| International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer (NCT02065765) | Eli Lilly and Company | |
| ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma. (NCT00040625) | Eli Lilly and Company | |
| An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes (NCT00065312) | Eli Lilly and Company | |
| EVA: Evista Alendronate Comparison (NCT00035971) | Eli Lilly and Company | |
| Pharmacokinetic Characterization of Intramuscular Olanzapine Depot (NCT00094640) | Eli Lilly and Company | |
| Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer. (NCT00034125) | Eli Lilly and Company | |
| Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor (NCT05225259) | Eli Lilly and Company | |
| Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer (NCT00097383) | Eli Lilly and Company | |
| Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer (NCT02792725) | Eli Lilly and Company | |
| A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. (NCT00035035) | Eli Lilly and Company | |
| Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer (NCT00055432) | Eli Lilly and Company | |
| Comparing 3 Schedules of Alimta Plus Gemzar (NCT00034606) | Eli Lilly and Company | |
| Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial (NCT00071708) | Eli Lilly and Company | |
| A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer. (NCT00034619) | Eli Lilly and Company | |
| Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis (NCT00046137) | Eli Lilly and Company | |
| Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes (NCT01724580) | Eli Lilly and Company | |
| Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma (NCT03994627) | Eli Lilly and Company | |